文献速递瓣膜病与结构性心脏病

AVCAPIR:钙化性主动脉瓣疾病中的新型促钙化PIWI相互作用RNA

AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease.
PubMed 文献 · Circulation · 2024-01-23

该研究鉴定了一种与主动脉瓣钙化相关的新型PIWI相互作用RNA(piRNA)AVCAPIR,其在钙化性主动脉瓣疾病(CAVD)中显著上调并具诊断价值。机制上,AVCAPIR通过阻断FTO去甲基化酶活性,经IGF2BP1稳定CD36 mRNA,进而稳定PCSK9蛋白,促进主动脉瓣钙化。

要点

  • AVCAPIR在主动脉瓣钙化中显著上调,有潜力作为CAVD诊断标志物。
  • 敲除AVCAPIR可减轻高胆固醇饮食ApoE-/-小鼠的主动脉瓣钙化及改善超声参数。
  • AVCAPIR通过FTO/CD36/PCSK9轴促进瓣膜间质细胞成骨分化。

核心结论

  • AVCAPIR是一种新型促钙化piRNA,通过RNA表观遗传机制诱导主动脉瓣钙化,为CAVD诊疗提供新思路。

研究设计与样本

  • 采用piRNA测序鉴定AVCAPIR,在高胆固醇饮食ApoE-/-小鼠中行AVCAPIR敲除,并在人瓣膜间质细胞中进行功能获得与缺失实验。

主要发现

  • AVCAPIR在主动脉瓣钙化中显著上调,具CAVD诊断潜力。
  • AVCAPIR敲除减轻小鼠主动脉瓣叶厚度和钙沉积,降低峰值跨瓣流速和平均跨瓣压差,增加主动脉瓣面积,减少Runx2和Osterix水平。
  • AVCAPIR直接结合FTO并阻断其N6-甲基腺苷去甲基化酶活性。
  • AVCAPIR阻碍FTO介导的CD36 mRNA去甲基化,经IGF2BP1增强CD36 mRNA稳定性。
  • CD36稳定PCSK9蛋白水平,加速主动脉瓣钙化进展。

临床怎么用

  • AVCAPIR可能作为CAVD的诊断标志物和潜在治疗靶点,但尚需临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calcification of the aortic valve leads to increased leaflet stiffness and consequently results in the development of calcific aortic valve disease (CAVD). However, the underlying molecular and cellular mechanisms of calcification remain unclear. Here, we identified a novel aortic valve calcification-associated PIWI-interacting RNA (piRNA; AVCAPIR) that increases valvular calcification and promotes CAVD progression. METHODS: Using piRNA sequencing, we identified piRNAs contributing to the pathogenesis of CAVD that we termed AVCAPIRs. High-cholesterol diet-fed ApoE-/- mice with AVCAPIR knockout were used to examine the role of AVCAPIR in aortic valve calcification (AVC). Gain- and loss-of-function assays were conducted to determine the role of AVCAPIR in the induced osteogenic differentiation of human valvular interstitial cells. To dissect the mechanisms underlying AVCAPIR-elicited procalcific effects, we performed various analyses, including an RNA pulldown assay followed by liquid chromatography-tandem mass spectrometry, methylated RNA immunoprecipitation sequencing, and RNA sequencing. RNA pulldown and RNA immunoprecipitation assays were used to study piRNA interactions with proteins. RESULTS: We found that AVCAPIR was significantly upregulated during AVC and exhibited potential diagnostic value for CAVD. AVCAPIR deletion markedly ameliorated AVC in high-cholesterol diet-fed ApoE-/- mice, as shown by reduced thickness and calcium deposition in the aortic valve leaflets, improved echocardiographic parameters (decreased peak transvalvular jet velocity and mean transvalvular pressure gradient, as well as increased aortic valve area), and diminished levels of osteogenic markers (Runx2 and Osterix) in aortic valves. These results were confirmed in osteogenic medium-induced human valvular interstitial cells. Using unbiased protein-RNA screening and molecular validation, we found that AVCAPIR directly interacts with FTO (fat mass and obesity-associated protein), subsequently blocking its N6-methyladenosine demethylase activity. Further transcriptomic and N6-methyladenosine modification epitranscriptomic screening followed by molecular validation confirmed that AVCAPIR hindered FTO-mediated demethylation of CD36 mRNA transcripts, thus enhancing CD36 mRNA stability through the N6-methyladenosine reader IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1). In turn, the AVCAPIR-dependent increase in CD36 stabilizes its binding partner PCSK9 (proprotein convertase subtilisin/kexin type 9), a procalcific gene, at the protein level, which accelerates the progression of AVC. CONCLUSIONS: We identified a novel piRNA that induced AVC through an RNA epigenetic mechanism and provide novel insights into piRNA-directed theranostics in CAVD.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Han D, Zhou T, Li L, et al. AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease. Circulation. 2024. PMID: 38258575. doi:10.1161/CIRCULATIONAHA.123.065213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。